信息图：我们如何缩小欧洲东西方医疗保健投资差距？

Over the past decades, CEE countries have modernised their health systems and increased theirpharmaceutical investments at a significantly faster rate than the EU4. However, CEE countriesinvest significantly less in health and medicines compared to the top European economies. Patients in CEE wait longer for innovation Insufficient budgets are correlated to disparities in patient access to innovativemedicines. Patients in CEE countries have access to less than half the number ofinnovative medicines and wait significantly longer than those in EU4 countries. Access to newEMA-authorised medicines Average timeto reimbursement Governments increasingly rely on highclawbacks and mandatory rebates tocontain overspending. This signalsstructural underbudgeting, nottemporary overspending. CEE health outcomes mirror theinvestment gap. Compared toEU4, CEE records: IN 2023 THE INDUSTRYCONTRIBUTION REACHED1/3 TO1/5OF THE PUBLICPHARMACEUTICALEXPENDITURE. HIGHER TREATABLEMORTALITY HUNGARY30.4% LOWER LIFE EXPECTANCY(78 VS 83 YEARS) BULGARIA23.5% An aging population increases pressure on healthcare spendingand threatens fiscal sustainability and economic growth CEE’s workforce willdecline by12.9 million,resulting in€14.6 billionin lost tax revenue. Healthcarespending ~3×higherafter the age of 55 What if CEE countries invested as much as the EU4 in health? Catching up to EU4 investment levels could saveover 100,000 lives and generate approximately€300 billion in economic impact. Key recommendations to close the gap: Strengthen sustainable,efficient health financing toimprove outcomesthroughforward-looking budgetingand reduced distortionarypayback mechanisms.1 Reduce barriers to timelyaccess to innovative medicinesthrough outcomes-basedpayment models, stronger HTAframeworks, and use of JointClinical Assessment outputs.2 Embed prevention andrisk-factor reduction asa core complement tohealth investment.3